

# Value IN HEALTH REGIONAL ISSUES

VOLUME 20 NUMBER C

DECEMBER 2019

TABLE OF CONTENTS

## BRIEF REPORT

- 2 Health Economics and Outcomes Research Knowledge Needs Assessment for Latin America**  
Valerie S. Hughes, André Luis Ferreira De Azeredo-Da-Silva, and Ana L. Hincapie
- 154 The Price of Substitute Technologies**  
André Soares Santos, Augusto Afonso Guerra-Junior, Kenya Valéria Micaela de Souza Noronha, Mônica Viegas Andrade, and Cristina Mariano Ruas

## ECONOMIC EVALUATION

- 7 Beneficio económico de los ensayos clínicos controlados patrocinados: El gasto evitable en medicamentos para el tratamiento de la artritis reumatoidea**  
Federico Liberman, Jorge Elgart, and Ingrid Strusberg
- 41 Cost-Effectiveness of a Technology-Enhanced Diabetes Care Management Program in Mexico**  
Todd Gilmer, Jose Luis Burgos, Maria Cecilia Anzaldo-Campos, and Adriana Vargas-Ojeda
- 60 The Public Health Benefits and Economic Value of Routine Yellow Fever Vaccination in Colombia**  
Alexia Kieffer, Celine Hoestlandt, Yaneth Gil-Rojas, Anaïs Broban, Camilo Castañeda-Cardona, and Diego Rosselli
- 73 Budgetary Impact of Oral Rehabilitation With Complete Dentures: An Economical Evaluation From São Paulo State, Brazil**  
Antonio Carlos Pereira, Luciana Ribeiro Bahia, Denise de Fátima Barros Cavalcante, Marcelo de Castro Meneghim, Yuri Wanderley Cavalcanti, Glaucia Maria Bovi Ambrosano, and Livia Fernandes Probst
- 79 Cost-Effectiveness of Bariatric Surgery Compared With Nonsurgical Treatment in People With Obesity and Comorbidity in Colombia**  
Yaneth Gil-Rojas, Andrés Garzón, Pieralessandro Lasalvia, Fabián Hernández, Camilo Castañeda-Cardona, and Diego Rosselli
- 86 Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective**  
Eleonora Aiello, Pablo Manuel Bianculli, Devarshi Bhattacharyya, Praveen Gunda, and Gustavo Citera
- 95 Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective**  
Helena H.L. Borba, Ursula Rochau, Astrid Wiens, Gaby Sroczynski, Uwe Siebert, Vinicius L. Ferreira, Eimy Minowa, and Roberto Pontarolo
- 103 Custo-utilidade de terapias-alvo comparadas à dacarbazina para o tratamento de primeira linha do melanoma avançado não-cirúrgico e metastático no Sistema Único de Saúde do Brasil**  
Renata Leborato Guerra, Flávia de Miranda Corrêa, Ricardo Ribeiro Alves Fernandes, and Ivan Ricardo Zimmerman
- 110 Costo de la intoxicación por Paraquat en Colombia**  
Jefferson Antonio Buendía and Gabriel Jaime Restrepo Chavarriaga

## TABLE OF CONTENTS - continued

- 115 Determining the Operating Costs of a Medical Surveillance Program for Copper Miners Exposed to High Altitude–Induced Chronic Intermittent Hypoxia in Chile Using a Combination of Microcosting and Time-Driven Activity-Based Costing**  
Roberto Reveco, Mónica Velásquez, Luis Bustos, Matías Goyenechea, and Vivienne Bachelet
- 122 Cost-Effectiveness of Proton Versus Photon Therapy in Pediatric Medulloblastoma Treatment: A Patient Volume–Based Analysis**  
Ricardo Ribeiro Alves Fernandes, Cid Manso de Mello Vianna, Renata Leborato Guerra, Marianna de Camargo Cancela, Liz Maria de Almeida, Adail José da Conceição Pereira, Célia Maria Pais Viégas, Sima Esther Ferman, and Flávia de Corrêa
- 136 Resource Utilization and Costs Associated With Percutaneous Coronary Intervention When Treating Patients With Acute Coronary Syndrome in the Mexican National Institute of Cardiology “Ignacio Chávez”**  
Kyla Jones, Jocelyn Ramirez, Manny Papadimitropoulos, Oscar S. Lomelí, Héctor Roque Vanegas, Evelyn Cortina de la Rosa, and Raúl Izaguirre Ávila
- 142 The Cost-Effectiveness of Continuous Versus Intermittent Renal Replacement Therapies in Acute Kidney Injury: Perspective of the Social Services for the Elderly in Argentina**  
Osvaldo Ulises Garay, Alfredo Palacios, Andrés Pichon-Riviere, Federico Augustovski, Sebastián García Martí, Akram Hernández-Vásquez, Elena Tapia López, Guillermo Rosa-Díez, and Ariel Bardach
- 149 Budget Impact of Cryoablation Versus Radiofrequency Ablation of Atrial Fibrillation in the Brazilian Public Healthcare System**  
Patricia Paço, Bernardo Tura, Marisa Santos, Pedro Amparo, and Andrea De Lorenzo
- 159 Economic Cost of Severe Acute Respiratory Infection Associated to Influenza in Colombian Children: A Single Setting Analysis**  
Fernando Salcedo-Mejía, Nelson J. Alvis-Zakzuk, María Carrasquilla-Sotomayor, Hernando Pinzón Redondo, Carlos Castañeda-Orjuela, Fernando De la Hoz-Restrepo, and Nelson Alvis-Guzmán
- 164 Cost of Patients With Hemophilia A and High-Titer Inhibitors in Colombia**  
Guillermo Sánchez-Vanegas, Adriana Linares, Isabel Sarmiento, María H. Solano, Giancarlo Romano, and Carlos Castro

## HEALTH POLICY ANALYSIS

- 12 New Challenges in Oncology for the Brazilian Private Health Sector: Specialists' Concerns After the ISPOR International Congress in Boston, Massachusetts, 2017**  
Marcos Santos, Stephen Stefani, Joao Paulo Reis Neto, and Manoel Carlos Santos
- 129 The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico**  
Daniela Moye-Holz, Jitse P. van Dijk, Sijmen A. Reijneveld, and Hans V. Hogerzeil

## METHODOLOGY

- 180 Epidemiología, consumo de recursos y costos del manejo médico de la Hepatitis C en Argentina, Colombia, Uruguay y Venezuela**  
Ariel Bardach, Akram Hernández-Vásquez, Alfredo Palacios, María Calderón, Natalie Soto, Dario Balan, and Federico Augustovski

## TABLE OF CONTENTS - continued

### PATIENT-REPORTED OUTCOMES

- 28**    **Prevalence of Symptoms and Symptom Clusters of Patients on Dialysis in Uruguay**  
Ana Inés Galain, Juan José Dapuelto, Ramón Alvarez, and Liliana Gadola
- 172**   **The Brazilian Portuguese Version of the DISCERN Instrument: Translation Procedures and Psychometric Properties**  
Patricia Logullo, Maria Regina Torloni, Carolina de O.C. Latorraca, and Rachel Riera

### POLICY PERSPECTIVE

- 36**    **Agnet y Judicialization en Salud en Argentina**  
Andrés Freiberg, Jorge Nicolás Lafferriere, and Martín Zambrano
- 47**    **In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments**  
P.N. Aguiar Jr, Jacob J. Adashek, Felipe Roitberg, Carmelia Maria Noia Barreto, Auro Del Giglio, and Gilberto L. Lopes Jr
- 51**    **Acuerdos de Riesgo Compartido: Lecciones Para su Diseño e Implementación a la Luz de la Experiencia Internacional**  
Daniela María Paredes Fernández and Rony Christian Lenz Alcayaga
- 66**    **Burden of Disease Attributable to Obesity and Overweight in Colombia**  
Yaneth Gil-Rojas, Andrés Garzón, Fabián Hernández, Bethia Pacheco, Daniela González, Juan Campos, Juan David Mosos, Julián Barahona, María José Polanía, Paula Restrepo, Pieralessandro Lasalvia, Camilo Castañeda-Cardona, and Diego Rosselli
- 191**   **Challenges in the Regulation of High-Cost Treatments: An Overview From Brazil**  
Lara C. Pereira, Daniela V.R. Sturzenegger, Juliana Ortiz, Nadia M.E. Ayad, Wilian A. Cortopassi, Leandro P. Safatle, and Natalia Khuri

### PREFERENCE-BASED ASSESSMENTS

- 21**    **A Comparison of UK and Brazilian SF-6D Preference Weights When Applied to a Brazilian Urban Population**  
Marcos Bosi Ferraz, Elene Paltrinieri Nardi, and Alessandro Gonçalves Campolina

### LETTERS TO THE EDITOR

- 1**    **Response to Letter to the Editor**  
María Calderón
- 19**    **Inflammatory Bowel Disease in Latin America: A Systematic Review**  
Daniela Simian and Rodrigo Quera
- 196**   **Correction**